{"slug":"vip-skin","verification":{"valid":true,"entries":1,"head":"2b4498150ceb340b6e589fc991add9cf5d3d101e0f3ab853020b2c9d3e740fa7"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.041764,"waste_cost_usd":0,"total_tokens":29670,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.041764,"tokens_total":29670,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:18:42.373Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Skin: Evidence-Graded Look at Vasoactive Intestinal Peptide Research","register":"source_ledger","body":"## What's breaking down\n\nSkin health depends on balanced repair and degeneration. When immune signaling and autonomic control of blood flow tip toward excess inflammation or poor tissue turnover, conditions like chronic redness, barrier weakness, or slow recovery can persist. VIP research focuses on its potential role in the immune and autonomic layers of skin. These layers involve cytokine balance, nerve-mediated vasodilation, and local cell migration. If degeneration here outruns normal repair signals, the skin stays stuck in a cycle of irritation rather than returning to baseline.\n\n## Why VIP might help you\n\nVIP is discussed in the context of immune and autonomic skin layers because studies explore its effects on tissue-level processes rather than symptom masking. \n\nIf your skin shows signs of immune-driven inflammation (such as elevated local cytokines or mast cell activity), VIP is examined for its ability to shift cytokine profiles toward resolution in certain models. \n\nIf autonomic regulation of skin blood flow feels disrupted (flushing, poor perfusion, or heat-related responses), human data on VIP-mediated vasodilation in skin suggests it participates in normal vessel control. \n\nIf tissue repair lags (slow epithelial closure or reduced cell movement), related cell studies look at migration and proliferation signals that VIP can influence in epithelial models. \n\nTherefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## How these fit together\n\nThis is a single-compound focus. VIP maps to the immune/autonomic layer. Any broader skin profile would pair it with compounds addressing other layers such as direct collagen support or barrier lipids. Here the emphasis stays on VIP's studied positions in cytokine modulation and vascular tone.\n\n## What the evidence actually shows\n\nHuman data remains limited. One study with 43 volunteers examined VIP's role in skin vasodilation during heat stress and found it contributes to active cutaneous vasodilation (Wilkins 2004, human). Another small human investigation tested VIP in established allergic contact dermatitis and noted potential immunomodulatory effects (Bondesson 1996, human). Serum VIP levels were higher in atopic dermatitis patients compared with controls in one report, though no direct correlation with severity appeared (Umemoto 2003, human). Skin tissue levels of VIP have been measured in atopic dermatitis lesions in other small series (Pincelli 1991, human).\n\nPreclinical work includes in vitro and animal models showing VIP can alter cytokine production and support epithelial cell migration in bronchial models (Guan 2006, human cells in vitro). Mouse arthritis models demonstrated reduced inflammation with VIP, but these do not address skin (Delgado 2001, mouse). Expression studies link VIP receptors to keratinocytes and suggest roles in inflammatory dermatoses such as psoriasis and atopic dermatitis (Kakurai 2001, human tissue; Kakurai 2009, human cells).\n\nAnecdotal reports on forums mention VIP in broader peptide contexts but rarely isolate skin outcomes. X posts occasionally note general improvements including skin after VIP use alongside other peptides, yet these remain individual reports without controlled conditions.\n\n## What scientists say\n\nResearchers describe VIP as an immunomodulatory neuropeptide that can inhibit pro-inflammatory cytokines like TNF-α and IL-6 while promoting anti-inflammatory signals in multiple models (Martínez 2019, review of animal and human cell data). In skin-specific contexts, papers note altered VIP signaling in atopic dermatitis and psoriasis lesions and call for further targeted studies. Human skin blood flow experiments confirm VIP participates in normal vasodilation pathways. Reviews emphasize that most protective effects come from animal or ex-vivo human samples; direct clinical trials for dermatologic use are absent.\n\n## What people say on Reddit\n\nDiscussions center more on copper peptides (GHK-Cu) for skin firmness and repair. Direct VIP mentions are sparse and usually appear in mold-recovery or gut-health threads rather than dedicated skincare. One post references VIP alongside other peptides for systemic symptoms that included skin, but no detailed before-after skin data or isolated skin protocols appear. Users generally treat VIP as a research compound with limited personal skin anecdotes.\n\n## What people say on X\n\nScattered posts describe subjective changes after VIP use. One user reported slight improvements in skin along with mood and energy. Another mentioned VIP in a multi-peptide stack that coincided with skin relief during illness recovery. These remain single-user observations without lab confirmation or controls. No widespread skin-specific threads surfaced.\n\n## What we do not know\n\nNo large randomized human trials test VIP for any skin condition. Dose, delivery method (systemic versus topical), duration, and long-term effects lack systematic data. Whether VIP shifts actual clinical outcomes like lesion clearance or barrier function in patients remains unproven. Interaction with common skin treatments or different skin types is unexplored. Elevated VIP in some dermatitis patients raises questions about whether supplementation would help or interact with existing levels.\n\n## Safety and limits\n\nVIP research in humans is mostly short-term physiologic studies. Side effects reported in those settings include changes in blood pressure or flushing consistent with its vasodilatory action. Broader safety profiles, especially with repeated use or in people with skin disease, have not been established in controlled trials. All claims here rest on mechanistic, preclinical, or small human observational data. This article separates those tiers and does not suggest any treatment approach.","claims":[{"id":"c1","text":"Human study with 43 volunteers showed VIP contributes to skin vasodilation during heat stress.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human physiologic evidence on skin blood flow layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:18:41.471Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Small human study examined VIP in established allergic contact dermatitis with immunomodulatory observations.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Rare direct human skin inflammation data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:18:41.471Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Serum VIP levels elevated in atopic dermatitis patients versus controls (one study).","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Human observational link between VIP and skin condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:18:41.471Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"VIP alters cytokine production and supports epithelial migration in human cell models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Mechanistic support for repair layer.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:18:41.471Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP receptors expressed in human keratinocytes; roles suggested in psoriasis and atopic dermatitis.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Tissue-level mechanistic data.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:18:41.471Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Mouse models show VIP reduces inflammation markers, though not skin-specific.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s6"],"source_status":"sourced","why_material":"Animal immunomodulation evidence.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:18:41.471Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c7","text":"X users report subjective skin improvements alongside other effects after VIP use.","section":"What people say on X","tier":"anecdotal","source_ids":["s7"],"source_status":"sourced","why_material":"Real-world user observations separated from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:18:41.471Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://journals.physiology.org/doi/full/10.1152/japplphysiol.00366.2004","title":"Mechanisms of vasoactive intestinal peptide-mediated vasodilation in human skin","quote":"Forty-three subjects volunteered to participate in two studies designed to examine the mechanism of VIP-mediated vasodilation in human skin.","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/8993464/","title":"Vasoactive intestinal polypeptide inhibits the established allergic contact dermatitis reaction in humans","quote":"In the present study the potential immunomodulatory role of vasoactive intestinal polypeptide (VIP) in established allergic contact dermatitis in humans was investigated.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://www.sciencedirect.com/science/article/abs/pii/S0923181103000045","title":"Serum levels of vasoactive intestinal peptide are elevated in patients with atopic dermatitis","quote":"The results showed that serum levels of VIP in AD patients (345.8±71.5 μg/ml) were significantly higher than those in healthy individuals (307.1±42.6 μg/ml).","link_status":"http_400","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16965837/","title":"Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells","quote":"The results showed that VIP accelerated the recovery of wound area of HBEC. VIP increased the migration and proliferation of HBEC.","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/11348464/","title":"Vasoactive intestinal peptide regulates its receptor expression in human keratinocytes","quote":"Vasoactive intestinal peptide has been suggested to play some roles in inflammatory dermatoses such as atopic dermatitis and psoriasis.","link_status":"ok","quote_status":"verified"},{"id":"s6","type":"other","url":"https://www.hopkinsarthritis.org/arthritis-news/vasoactive-intestinal-peptide-vip-prevents-experimental-arthritis-news-summary-from-johns-hopkins-arthritis/","title":"Vasoactive Intestinal Peptide (VIP) Prevents Experimental Arthritis","quote":"Mice treated with VIP showed delayed onset, lower incidence and decreased severity of CIA in comparison with placebo-treated arthritic mice.","link_status":"ok","quote_status":"verified"},{"id":"s7","type":"x","url":"https://x.com/Tribilus1333733/status/1913689771244945713","title":"X post on VIP effects","quote":"VIP peptide has given me slight improvements in mood, energy, skin, and hemorrhoids.","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":25929,"tokens_out":3741,"cost":0.04176375,"prev_hash":"genesis","hash":"2b4498150ceb340b6e589fc991add9cf5d3d101e0f3ab853020b2c9d3e740fa7"}]}